Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

AACR 2023 | Intratumoral MEDI1191 encoding IL-12 in solid tumors

Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, provides an overview of the Phase I trial (NCT03946800) assessing MEDI1191, an injectable lipid nanoparticle-formulated therapy containing mRNA encoding IL-12. Whilst there were responses in terms of activation of the immune system, especially in patients with melanoma, the primary endpoint was not met. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.